Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made
Its important to note that these figures can fluctuate based on individual circumstances and should be considered as part of a broader, personalized weight management plan developed in collaboration with healthcare providers like those at Primary Care of Clear Lake
Its licensing status can be verified via the MHRA's products database (products.mhra.gov.uk), the EMA's medicines pipeline (ema.europa.eu), and the FDA's Drugs@FDA database (fda.gov)
The GLP-1 Foundation Semaglutide (sold as Ozempic for type 2 diabetes and Wegovy for weight management) works primarily by mimicking glucagon-like peptide-1 (GLP-1)
Mechanism of Action: Semaglutide GLP-1 works by activating GLP-1 receptors in the brain and pancreas, resulting in several key benefits: Delayed Gastric Emptying: By slowing the rate at which food exits the stomach, semaglutide GLP-1 helps promote a feeling of fullness and reduces hunger, assisting in decreased calorie consumption
GLP-3 is the name used here to describe a synthetic research peptide known in scientific literature as retatrutide
